Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206530 · ClinicalTrials.gov registry record · Phase 1
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT01206530 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 50 participants.
The verdict
NCT01206530, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab. In toxicity terms, the investigators previous studies lead them to believe that a full dose (800mg) of HCQ will be well-tolerated in this setting. By starting at 600 mg, the investigators will ensure that the full dose is approached with an eye to safety, and if needed, the investigators will use the lower dose. Both doses achieve autophagy inhibition in our current studies.
Interventions
- DRUG Leucovorin
- DRUG Oxaliplatin
- DRUG 5-fluorouracil
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2010-09 |
| Est. Completion | 2017-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01206530
The ClinicalTrials.gov registry entry for NCT01206530 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT01206530 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01206530 about?
NCT01206530 is a clinical study titled "FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer". In this Phase I/II clinical trial, the investigators seek to pilot the addition of hydroxychloroquine (HCQ) to the standard front-line therapy of colorectal cancer, FOLFOX/bevacizumab. In toxicity terms, the investigators previous studies lead them to believe that a full dose (800mg) of HCQ will be ...
What is the current status of trial NCT01206530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2010-09. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01206530?
The interventions under investigation include: Leucovorin (DRUG), Oxaliplatin (DRUG), 5-fluorouracil (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT01206530?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.